Complexa Raises $62 Million to Continue Trials of Its Pulmonary Hypertension Therapy CXA-10
Complexa has obtained $62 million in financing to continue advancing its pulmonary arterial hypertension therapy CXA-10 through the clinical trial process. The company is also developing CXA-10 as a treatment for kidney disease focal segmental glomerulosclerosis, or FSGS. Companies that participated in Complexa’s third round of financing included New Enterprise…